This paper is in the following e-collection/theme issue:

RCTs - Protocols/Proposals (non-eHealth) (406) Depression and Mood Disorders; Suicide Prevention (1702) Methods and New Tools in Mental Health Research (561)

Published on in Vol 11, No 1 (2022): January

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/30163, first published .
The Safety, Clinical, and Neurophysiological Effects of Intranasal Ketamine in Patients Who Do Not Respond to Electroconvulsive Therapy: Protocol for a Pilot, Open-Label Clinical Trial

The Safety, Clinical, and Neurophysiological Effects of Intranasal Ketamine in Patients Who Do Not Respond to Electroconvulsive Therapy: Protocol for a Pilot, Open-Label Clinical Trial

The Safety, Clinical, and Neurophysiological Effects of Intranasal Ketamine in Patients Who Do Not Respond to Electroconvulsive Therapy: Protocol for a Pilot, Open-Label Clinical Trial

Authors of this article:

Yuliya Knyahnytska1 Author Orcid Image ;   Reza Zomorrodi1 Author Orcid Image ;   Tyler Kaster1 Author Orcid Image ;   Daphne Voineskos1 Author Orcid Image ;   Alisson Trevizol1 Author Orcid Image ;   Daniel Blumberger1 Author Orcid Image
Article Authors Cited by (2) Tweetations (4) Metrics

Journals

  1. Bharmauria V, Ramezanpour H, Ouelhazi A, Yahia Belkacemi Y, Flouty O, Molotchnikoff S. KETAMINE: Neural- and network-level changes. Neuroscience 2024;559:188 View
  2. Raza A, Ahmed G, Zafar H, Akhtar S, Bin Mobin M, Samadi A. Spravato for Treatment-Resistant Depression: Efficacy and Sexual Side Effect Profile. Neuropsychiatric Disease and Treatment 2025;Volume 21:2125 View